source
- Novo reports 25% average weight loss in women using CagriSema, with greatest loss in premenopausal patientsNovo's next-generation GLP-1 drug CagriSema showed substantial weight loss in women enrolled in the Phase 3 REDEFINE 1 trial. Women in the study lost about 25% of their body weight after 68 weeks,…
- FDA cites Baxter’s inadequate oversight after repeated GMP violations at multiple plantsThe U.S. Food and Drug Administration has issued a warning letter to Baxter International, saying the company's leadership has failed to provide adequate oversight of its drug manufacturing operati…